19 Apr 2021 13:21
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Further National Microbiology Framework contract award
Successful tender under Lot 4 (Clinical Laboratory Diagnostic Testing Services) valued at £15bn
Manchester, UK - 19 April 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Public Health England ("PHE") has confirmed that Yourgene has been successful with its tender under PHE's National Microbiology Framework for Lot 4 (Clinical Laboratory Diagnostic Testing Services).
Lot 4 is a £15bn Framework to be satisfied over a period of four years by multiple successful bidders, with only 50 companies appointed to this lot.
PHE's National Microbiology Framework is appointing suppliers to framework agreements for four lots. Awards under Lot 1 and Lot 4 have been announced and cover the supply of Diagnostics Goods and Services, including Clinical Laboratory Diagnostic Testing Services. Yourgene announced earlier today that it had been successful with its tender for Lot 1 (Diagnostic Goods and Services).
Yourgene will be able to offer its Clarigene® SARS-CoV-2 PCR assay and associated Manchester-based clinical laboratory testing services under the Framework Agreement.
Whilst the Framework Agreement is not exclusive to Yourgene, or a guarantee of orders, it does allow participating public health authorities across the UK to issue call-off contracts to procure goods and testing services from Yourgene, amongst other providers, going forward.
Lyn Rees, CEO of Yourgene commented:
"We are delighted with the further successful tender award under Lot 4 of the Microbiology Framework. This reinforces the reputation of our accredited lab based COVID testing services and we look forward to updating shareholders should we secure future call-off contracts under this framework agreement."
This announcement contains inside information for the purposes of UK Market Abuse Regulation. The Directors of the Company take responsibility for this announcement.
Yourgene Health plc Lyn Rees, Chief Executive Officer | Tel: +44 (0)161 669 8122 investors@yourgene-health.com | |||
Barry Hextall, Chief Financial Officer |
| |||
Joanne Cross, Director of Marketing |
| |||
|
| |||
Cairn Financial Advisers LLP (NOMAD) | Tel: +44 (0)20 7213 0880 | |||
Liam Murray / James Caithie / Ludovico Lazzaretti |
| |||
N+1 Singer (Joint Corporate Broker) | Tel: +44 (0)20 7496 3000 | |||
Aubrey Powell / Tom Salvesen / George Tzimas |
| |||
|
| |||
Stifel Nicolaus Europe Limited (Joint Corporate Broker) | Tel: +44 (0)20 7710 7600 | |||
Nicholas Moore / Matthew Blawat / Ben Maddison |
| |||
|
| |||
Walbrook PR Ltd (Media and Investor Relations) | Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com | |||
Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / Mob: 07584 391 303 | |||
|
|
|
| |
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.